What has been recommended?
NICE recommended relugolix–estradiol–norethisterone in April 2025 and linzagolix with hormonal add-back therapy in June 2025 for adults of reproductive age who have already had medical or surgical treatment for endometriosis.
These are oral GnRH antagonist options. Add-back therapy uses hormones to reduce some of the effects of lowering natural hormone levels.
Who might benefit?
Suitability depends on the symptoms being treated, earlier treatment, other health conditions, side effects and pregnancy plans. A new recommendation does not mean that someone doing well on an existing treatment needs to switch.
Your clinician can explain the expected benefit, risks, monitoring and what would lead to a treatment change. Prescribing and access arrangements should be confirmed with the relevant service.
Questions for your consultation
- What is the goal of another hormonal treatment in my case?
- How does it compare with my current treatment?
- What are the implications for bone health and pregnancy planning?
- What monitoring and review would I need?
- What happens if it is ineffective or poorly tolerated?
Medicines, pain care and surgery have different roles. A recommendation should fit the whole treatment plan.
Information sources
- NICE TA1057: relugolix combination therapy
- NICE TA1067: linzagolix with add-back therapy
- NICE TA1067: information for the public (PDF)
General information to support your consultation. Individual assessment is needed to decide on treatment.